ChromoCure Completes Realignment of Management as First Step in Transition to Cancer Therapy and Cure Research & Development
March 01 2010 - 12:50PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the completion
of the first major step in its transition to a focused Cancer
Therapy and Cure Research & Development organization. The
Company recently announced its accelerated Therapy and Cure
initiatives through the launch of Project Boveri: Find the Cure;
properly reflecting its pioneering role in cancer detection,
therapy and cure; and its increased research programs and
collaborations.
This major realignment of the Company's business strategy
includes the departure of all prior management. The Company will
soon announce its new management team with proven credentials to
maintain ChromoCure's leadership and pioneering role in Cancer
Therapy and Cure initiatives worldwide.
As recently announced the Company had realigned its business
strategy due to corroboration by recent Medical Research
publications that both validated ChromoCure's
chromosomal/aneuploidy theory of cancer and immediately established
the company's proprietary Chromosomal Scanner technology in the
forefront of both cancer detection and research.
Research has conclusively, and irrefutably demonstrated
aneuploidy as a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's proprietary technology and understanding of cancer
also suggest non-toxic and non-invasive approaches to cancer
therapy and cure research.
The company's technology and research combined with unique
insights provided by the chromosomal theory of cancer paves the way
for non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. ChromoCure's ChromoSomal Scanner Technologies,
encompassing proprietary designs, processes, and algorithms,
provides significant advantage in delivering important and
significant results in diagnosis therapy and cure.
Support by these recent third party medical findings, the
Company is calling for a stepped up collaborative approach through
its "Project Boveri: Find the Cure" initiative; and is inviting
industry, institutions, medical research centers and government to
partner in this initiative. The company has already established a
special section of its web site dedicated to this project and
research outreach. The Company's recently announced diagnostic
partnership program with pathologists and diagnostic labs will be
incorporated into Project Boveri in order to broaden awareness of
the company's technology.
The company will provide timely updates on new management as
well as progress reports on new management appointments; as well as
partnerships, products, licensing, and laboratory activities based
on this research-oriented alignment.
About ChromoCure ChromoCure develops and
provides proprietary cancer detection systems and related
therapeutic technologies. The Company's proprietary CS200
Chromosomal Scanner has been proven accurate and efficient in the
measurement of the unique genomic characteristic found in 100% of
all cancers and never found in normal cells. The Company's
detection technology has an effective accuracy of 100% for all
cancers at all stages. The Company believes its technology will
become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024